Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Schedule of Change in Accounts Receivable, Contract Assets and Liabilities (Details)

v3.22.2.2
Collaboration and Research Arrangements - Schedule of Change in Accounts Receivable, Contract Assets and Liabilities (Details)
 9 Months Ended
Sep. 30, 2022
USD ($)
Disaggregation Of Revenue [Line Items]  
Accounts receivable and contract assets, Balance at Beginning of Period $ 2,979,000
Accounts receivable and contract assets, Additions 15,764,000
Accounts receivable and contract assets, Deductions (16,972,000)
Accounts receivable and contract assets, Balance at End of Period 1,771,000
Contract liabilities, Balance at Beginning of Period 10,181,000
Contract liabilities, Additions 199,000
Contract liabilities, Deduction (8,755,000)
Contract liabilities, Balance at End of Period 1,625,000
Incyte  
Disaggregation Of Revenue [Line Items]  
Contract liabilities, Balance at Beginning of Period 1,268,000
Contract liabilities, Deduction (1,228,000)
Contract liabilities, Balance at End of Period 40,000.0
Global Blood Therapeutics  
Disaggregation Of Revenue [Line Items]  
Contract liabilities, Balance at Beginning of Period 8,913,000
Contract liabilities, Additions 199,000
Contract liabilities, Deduction (7,527,000)
Contract liabilities, Balance at End of Period 1,585,000
Billed receivables from collaboration partners  
Disaggregation Of Revenue [Line Items]  
Accounts receivable, Additions 8,288,000
Accounts receivable, Deduction (8,288,000)
Unbilled receivables from collaboration partners  
Disaggregation Of Revenue [Line Items]  
Contract assets, Balance at Beginning of Period 2,979,000
Contract assets, Additions 7,476,000
Contract assets, Deduction (8,684,000)
Contract assets, Balance at End of Period $ 1,771,000